NCT06573294View on ClinicalTrials.gov

Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 28, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

January 31, 2026

Conditions
Advanced Malignant Solid TumorMetastatic Malignant Solid Tumor
Interventions
DRUG

GEN1057

Intravenous (IV) infusion

DRUG

Premedication

IV infusion/orally by mouth.

Trial Locations (5)

28050

RECRUITING

Start Madrid Centro Integral Oncologico Clara Campal CIOCC, Madrid

37203

RECRUITING

SCRI Oncology Partners, Nashville

78229

RECRUITING

South Texas Accelerated Research Therapeutics, LLC, San Antonio

Unknown

RECRUITING

National Cancer Center, Tsukiji 5-1-1, Tokyo

08035

RECRUITING

Hospital Universitari Vall d'Hebron, Barcelona

Sponsors

Lead Sponsor

Genmab
All Listed Sponsors
lead

Genmab

INDUSTRY

NCT06573294 - Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors | Biotech Hunter | Biotech Hunter